Dr. Vinay Prasad, the head of vaccines and biologic medicines at the U.S. Food and Drug Administration (FDA), will leave his post at the end of April. His departure comes amid a series of controversial decisions involving vaccine reviews and specialty drugs for rare diseases.
Key Takeaways
FDA vaccine chief Dr. Vinay Prasad will leave his post at the end of April amid controversies over vaccine and drug reviews. His departure follows public disputes with pharmaceutical companies and ethical concerns raised by some decisions.
- Dr. Vinay Prasad to depart FDA at the end of April
- Departure follows multiple controversies involving vaccine and drug reviews
- Public disputes include Moderna's mRNA flu vaccine and UniQure's gene therapy for Huntington’s disease
- Prasad previously left in July 2023 but was reinstated with support from Health Secretary Robert F. Kennedy Jr.
- FDA spokesperson emphasizes decisions are based on evidence
The announcement was made by FDA Commissioner Marty Makary in an email to staff late Friday. Prasad, who initially joined the FDA last May, will return to his academic position at the University of California, San Francisco. This marks his second departure from the agency within less than a year.
In July 2023, Prasad was briefly forced out after facing criticism from biotech executives, patient groups, and conservative allies of President Donald Trump. He was reinstated two weeks later with the backing of Health Secretary Robert F. Kennedy Jr. and Makary.
The latest controversies include Prasad's initial refusal to review Moderna's highly anticipated mRNA flu vaccine, a decision that was later reversed after public backlash. Additionally, the FDA engaged in an unusual public dispute with UniQure, a small drug company developing a gene therapy for Huntington’s disease. The FDA demanded additional trials involving sham surgeries on patients, which UniQure executives argued contradicted previous guidance and raised ethical concerns.
Prasad's tenure has been marked by disputes with companies over the FDA's review process, leading to requests for new trials and adding significant costs and delays to drug development. Despite efforts to streamline reviews, Prasad imposed new warnings and study requirements for some biotech drugs and vaccines, particularly COVID-19 shots, which have long been a target of Kennedy.
A former FDA official described the reversals in decisions as creating regulatory uncertainty, stifling the development of treatments for hard-to-treat diseases. The FDA spokesperson countered that there is 'no regulatory uncertainty,' emphasizing that decisions are based on evidence and not assurances about outcomes.
How this summary was created
This summary synthesizes reporting from 7 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.